DNDi E-news
November 2016  |   View Online

DNDi’s strategy to address the needs of children living with HIV

DNDi's paediatric HIV portfolio consists of three main areas: a large implementation study to help roll out lopinavir/ritonavir pellets, so that children no longer have to take horrid tasting syrups needing refrigeration; a study to confirm the best antiretroviral doses for children co-infected with TB, which has provided evidence in support of WHO guidelines; and longer-term, the development of taste-masked, heat-stable formulations combining four drugs, to ease treatment for infants and young children.»

DNDi-supported study shows Loa Loa infection is not as benign as assumed

The filarial worm infection Loa Loa, which affects over 10 million people in Africa, has until now largely been assumed to be relatively harmless, and thus received little attention from researchers and health authorities. But a new DNDi-funded study strongly suggests Loa Loa infection has a significant impact on life expectancy. What implications for researchers and for WHO? »

Governments recognize that business as usual is not enough to counter antimicrobial resistance

DNDi welcomed the commitment expressed by world leaders at the High-Level Meeting on Antimicrobial Resistance in September - the fourth time in its history the UN General Assembly has elevated a health issue to crisis level. The Political Declaration highlights the need to break the link between the cost of R&D and the sales of life-saving medical tools, and to ensure that public financing for research and innovation delivers a public return.»

New, simpler diagnostic algorithm for Colombia to facilitate detection of Chagas

To overcome the lack of access to treatment for people with Chagas, DNDi is working with national authorities in Colombia to assess the feasibility of scaling up access to diagnosis and treatment and validate a model of care for the disease. A step forward has been taken with the adoption of a new diagnostic algorithm that will allow for detection of Chagas cases through a simpler procedure, done at the primary health care level.»

UN High-Level Panel report and Lancet Commission both call for R&D framework

Both the UN Secretary-General Panel report and the Lancet Commission on Essential Medicines recently called on countries to initiate talks on an R&D Convention that delinks the cost of innovation from prices. Among other recommendations, the UN report also called on countries to negotiate a Code of Principles to ensure innovation delivers affordable and accessible products; to require greater transparency on R&D costs; and to ensure a public return on tax-payer funded contributions to R&D. The Lancet Commission also called for the creation of a list of missing essential medicines to help set R&D priorities.

Uganda to adopt LPV/r pellets in its HIV paediatric treatment guidelines

In 2017, Uganda will begin using lopinavir/ritonavir (LPV/r) pellets as a key part of treatment for children living with HIV. Until the development of the pellets in 2015, the only available version of LPV/r for kids was a harsh-tasting syrup that requires refrigeration and contains 40% alcohol. DNDi’s LIVING study in Kenya, Uganda, South Africa,Tanzania, and Zambia aims to provide early access to the new formulation.

Scientific Articles

Journal of Biomolecular Screening
Evaluation of parameters impacting drug susceptibility in intracellular T. cruzi assay protocols »

Scientific Reports
Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage »

A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites »

PLOS Neglected Tropical Diseases
Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial »

International Journal for Parasitology: Drugs and Drug Resistance
Assessing anti-T. cruzi candidates in vitro for sterile cidality »

PLOS Neglected Tropical Diseases
Transmission dynamics of visceral leishmaniasis in the Indian subcontinent - A systematic literature review »

The Lancet
Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated P. falciparum malaria in children under 5 yrs in sub-Saharan Africa: a randomised, multicentre, phase 4 trial »
Photo credits:
DNDi/Mariella Furrer, DNDi
/Benoît Marquet
Nuevo algoritmo-diagnóstico para Chagas en Colombia para un procedimiento más sencillo»

Los desafíos relacionados con Investigación y Desarrollo»

Novo algoritmo-diagnóstico para Chagas na Colômbia para um procedimento mais simples»

Os desafios que envolvem Pesquisa e Desenvolvimento»


WorldLeish 6
Toledo, 16-20 May 2017
From basic research to vector control and disease elimination, from canine leishmaniasis to neglected patients’ needs, from drug discovery to clinical trials and advocacy, the Congress will cover all scientific and policy aspects of leishmaniasis today.
Extended deadline for abstract submission is December 16, 2016.

ASTMH 2016
Atlanta, 13-17 November 2016

10º ENIFarMed
São Paulo, 17-18 October 2016
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2016 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book

Unsubscribe from this list.